Update on the Potential Use of Natural Triterpenes for the Treatment of Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic-Dysfunction-Associated Steatohepatitis (MASH)
Livers · 02.06.2026 · 6 (3) · 48
DOI: 10.3390/livers6030048 ↗Kurz gefasst
Fachartikel in der Zeitschrift Livers, online erschienen am 02.06.2026. Verfasst von Izabela de Castro Santiago und 4 weiteren Autor:innen. Die Arbeit nennt 218 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de Minas Gerais, Conselho Nacional de Desenvolvimento Científico e Tecnológico, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Abstract (Originalsprache)
Background/Objectives: Metabolic-dysfunction-associated steatotic liver disease (MASLD) and its progressive inflammatory/fibrotic form, metabolic-dysfunction-associated steatohepatitis (MASH), represent a growing global health burden. This progression is driven by complex mechanisms involving metabolic dysregulation, chronic inflammation, oxidative stress, and progressive fibrosis. To date, effective pharmacological therapies remain limited. Pentacyclic triterpenes have attracted increasing attention due to their broad biological activities and ability to modulate multiple molecular pathways implicated in chronic liver disease. This review aims to provide a mechanistic overview of the potential role of pentacyclic triterpenes in MASLD and MASH.
Methods
A literature review was conducted using major scientific databases (PubMed and Web of Science) to identify experimental studies investigating pentacyclic triterpenes in metabolic liver diseases. Selected studies were analyzed according to triterpene structural classification, reported bioactivities, molecular targets, and experimental evidence from in vitro and in vivo models of MASLD/MASH or related pathogenic processes.
Results
Pentacyclic triterpenes, especially ursolic acid, oleanolic acid, and glycyrrhizin, exhibit hepatoprotective effects including regulation of lipid metabolism, attenuation of oxidative and endoplasmic reticulum stress, suppression of pro-inflammatory signaling, inhibition of inflammasome activation, and reduction in hepatic stellate cell activation and extracellular matrix deposition. These effects involve modulation of signaling pathways, including AMPK, NF-κB, NLRP3, TGF-β, FXR, and MAPK. Preclinical evidence demonstrates improvements in steatosis, inflammation, and fibrosis in experimental models.
Conclusions
Pentacyclic triterpenes emerge as multitarget modulators of MASH pathophysiology. However, translating preclinical evidence into well-designed clinical trials is necessary to validate their safety and efficacy in humans.
Förderung
- Fundação de Amparo à Pesquisa do Estado de Minas Gerais
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Zitieren
APA
Santiago, I. D. C., Lemos, J. D. A., Silva, I. M., Oliveira, A. E. M. D. F. M., & Ferreira, D. D. S. (2026). Update on the Potential Use of Natural Triterpenes for the Treatment of Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic-Dysfunction-Associated Steatohepatitis (MASH). Livers, 6(3), 48. https://doi.org/10.3390/livers6030048
Vancouver
Santiago IDC, Lemos JDA, Silva IM, Oliveira AEMDFM, Ferreira DDS. Update on the Potential Use of Natural Triterpenes for the Treatment of Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic-Dysfunction-Associated Steatohepatitis (MASH). Livers. 2026;6(3):48. doi:10.3390/livers6030048
BibTeX
@article{Santiago2026,
author = {Santiago, Izabela de Castro and Lemos, Janaina de Alcântara and Silva, Ivan Maulaz and Oliveira, Anna Eliza Maciel de Faria Mota and Ferreira, Diego dos Santos},
title = {Update on the Potential Use of Natural Triterpenes for the Treatment of Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic-Dysfunction-Associated Steatohepatitis (MASH)},
journal = {Livers},
year = {2026},
volume = {6},
number = {3},
pages = {48},
doi = {10.3390/livers6030048}
}
EUVIMED